PSMB8-AS1: A Promising Drug Target / Biomarker (G100507463)

Target Name: PSMB8-AS1

NCBI ID: G100507463

PSMB8-AS1

Other Name(s): PSMB8 antisense RNA 1 (head to head) | TAPSAR1 | PSMB8 antisense RNA 1 (head to head), transcript variant 1 | TAP1-AS1

PSMB8-AS1: A Promising Drug Target / Biomarker

PSMB8-AS1 is a protein that is expressed in various tissues of the body, including the brain, pancreas, and muscle. It is a member of the PSMB family, which includes proteins that are involved in the detoxification of xenobiotics, such as drugs and other harmful substances. The PSMB8 gene has been identified as a potential drug target for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

The Protein Structure and Functions

PSMB8-AS1 is a member of the PSMB family, which consists of six structurally similar proteins. These proteins share a conserved catalytic core and a hydrophobic tail, which is involved in protein-protein interactions and localization in the cell. The N-terminus of each PSMB protein contains a variable region that is involved in the detoxification of xenobiotics.

PSMB8-AS1 is a 140-kDa protein that is expressed in various tissues of the body, including the brain, pancreas, and muscle. It is highly conserved, with a calculated amino acid identity of 97% between the human and mouse genomes. PSMB8-AS1 is localized to the endoplasmic reticulum (ER) and can be detected in a variety of tissues using antibodies that recognize its specific epitopes.

Drug Sensitivity and Inhibitors

PSMB8-AS1 is a drug target of interest for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Several studies have demonstrated the sensitivity of cancer cells to inhibitors that interact with PSMB8-AS1, such as a small molecule inhibitor and a monoclonal antibody (7,8). These inhibitors have been shown to reduce the growth of cancer cells, including human breast, ovarian, and prostate cancer cells (7,8).

In addition to inhibitors, there are also drugs that are designed to specifically target PSMB8-AS1, such as a small molecule inhibitor that binds to a specific epitope on the protein (9) and a monoclonal antibody that recognizes a specific epitope on the protein. These drugs have been shown to be effective in preclinical studies in treating various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases (9,10).

Targeting PSMB8-AS1

PSMB8-AS1 is a protein that is expressed in various tissues of the body and is involved in the detoxification of xenobiotics. As a drug target, PSMB8-AS1 can be targeted using various approaches, including inhibitors, antibodies, and small molecules.

Inhibitors can be designed to specifically interact with a specific epitope on PSMB8-AS1. For example, a small molecule inhibitor that binds to a specific epitope on the protein has been shown to reduce the growth of cancer cells. Similarly, a monoclonal antibody that recognizes a specific epitope on the protein has been shown to be effective in preclinical studies in treating various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases (9,10).

Conclusion

PSMB8-AS1 is a protein that is involved in the detoxification of xenobiotics and is a potential drug target for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its high conservation and localization to the endoplasmic reticulum make it an attractive target for small molecules and antibodies. Further research is needed to develop effective inhibitors and antibodies that can specifically target PSMB8-AS1 and to investigate its potential as a drug.

Protein Name: PSMB8 Antisense RNA 1 (head To Head)

The "PSMB8-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PSMB8-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets